Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing

Tumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly i...

Full description

Bibliographic Details
Main Authors: Lele Song, Yuan Gong, Erpeng Wang, Jianchun Huang, Yuemin Li
Format: Article
Language:English
Published: SAGE Publishing 2024-04-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231210274
_version_ 1797214438759071744
author Lele Song
Yuan Gong
Erpeng Wang
Jianchun Huang
Yuemin Li
author_facet Lele Song
Yuan Gong
Erpeng Wang
Jianchun Huang
Yuemin Li
author_sort Lele Song
collection DOAJ
description Tumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly influence lung cancer development and therapeutic outcome. The heterogeneity of TIME is composed of dynamic immune-related components, including various cancer cells, immune cells, cytokine/chemokine environments, cytotoxic activity, or immunosuppressive factors. The specific composition of cell subtypes may facilitate or hamper the response to immunotherapy and influence patient prognosis. Various markers have been found to stratify the patient prognosis or predict the therapeutic outcome. In this article, we systematically reviewed the recent advancement of TIME studies in lung adenocarcinoma (LUAD) using single-cell RNA sequencing (scRNA-seq) techniques, with specific focuses on the roles of TIME in LUAD development, TIME heterogeneity, indications of TIME in patient prognosis and therapeutic response during immunotherapy and drug resistance. The main findings in TIME heterogeneity and relevant markers or models for prognosis stratification and response prediction have been summarized. We hope that this review provides an overview of TIME status in LUAD and an inspiration for future development of strategies and biomarkers in LUAD treatment.
first_indexed 2024-04-24T11:14:11Z
format Article
id doaj.art-a42f93ab98394008a21967391f9f3588
institution Directory Open Access Journal
issn 1758-8359
language English
last_indexed 2024-04-24T11:14:11Z
publishDate 2024-04-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Medical Oncology
spelling doaj.art-a42f93ab98394008a21967391f9f35882024-04-11T10:04:01ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-04-011610.1177/17588359231210274Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencingLele SongYuan GongErpeng WangJianchun HuangYuemin LiTumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly influence lung cancer development and therapeutic outcome. The heterogeneity of TIME is composed of dynamic immune-related components, including various cancer cells, immune cells, cytokine/chemokine environments, cytotoxic activity, or immunosuppressive factors. The specific composition of cell subtypes may facilitate or hamper the response to immunotherapy and influence patient prognosis. Various markers have been found to stratify the patient prognosis or predict the therapeutic outcome. In this article, we systematically reviewed the recent advancement of TIME studies in lung adenocarcinoma (LUAD) using single-cell RNA sequencing (scRNA-seq) techniques, with specific focuses on the roles of TIME in LUAD development, TIME heterogeneity, indications of TIME in patient prognosis and therapeutic response during immunotherapy and drug resistance. The main findings in TIME heterogeneity and relevant markers or models for prognosis stratification and response prediction have been summarized. We hope that this review provides an overview of TIME status in LUAD and an inspiration for future development of strategies and biomarkers in LUAD treatment.https://doi.org/10.1177/17588359231210274
spellingShingle Lele Song
Yuan Gong
Erpeng Wang
Jianchun Huang
Yuemin Li
Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
Therapeutic Advances in Medical Oncology
title Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
title_full Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
title_fullStr Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
title_full_unstemmed Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
title_short Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
title_sort unraveling the tumor immune microenvironment of lung adenocarcinoma using single cell rna sequencing
url https://doi.org/10.1177/17588359231210274
work_keys_str_mv AT lelesong unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing
AT yuangong unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing
AT erpengwang unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing
AT jianchunhuang unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing
AT yueminli unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing